4PID | pdb_00004pid

Crystal structure of human adenovirus 2 protease with a weak pyrimidine nitrile inhibitor


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.59 Å
  • R-Value Free: 
    0.189 (Depositor), 0.187 (DCC) 
  • R-Value Work: 
    0.165 (Depositor), 0.163 (DCC) 
  • R-Value Observed: 
    0.166 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 4PID

Ligand Structure Quality Assessment 


This is version 1.3 of the entry. See complete history

Literature

Discovery and structure-based optimization of adenain inhibitors.

Mac Sweeney, A.Grosche, P.Ellis, D.Combrink, K.Erbel, P.Hughes, N.Sirockin, F.Melkko, S.Bernardi, A.Ramage, P.Jarousse, N.Altmann, E.

(2014) ACS Med Chem Lett 5: 937-941

  • DOI: https://doi.org/10.1021/ml500224t
  • Primary Citation Related Structures: 
    4PID, 4PIE, 4PIQ, 4PIS

  • PubMed Abstract: 

    The cysteine protease adenain is the essential protease of adenovirus and, as such, represents a promising target for the treatment of ocular and other adenoviral infections. Through a concise two-pronged hit discovery approach we identified tetrapeptide nitrile 1 and pyrimidine nitrile 2 as complementary starting points for adenain inhibition. These hits enabled the first high-resolution X-ray cocrystal structures of adenain with inhibitors bound and revealed the binding mode of 1 and 2. The screening hits were optimized by a structure-guided medicinal chemistry strategy into low nanomolar drug-like inhibitors of adenain.


  • Organizational Affiliation
    • Novartis Institute for Biomedical Research , Novartis Campus, CH-4002 Basel, Switzerland.

Macromolecule Content 

  • Total Structure Weight: 24.77 kDa 
  • Atom Count: 1,918 
  • Modeled Residue Count: 215 
  • Deposited Residue Count: 215 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Protease204Human adenovirus 2Mutation(s): 0 
Gene Names: L3
EC: 3.4.22.39
UniProt
Find proteins for P03252 (Human adenovirus C serotype 2)
Explore P03252 
Go to UniProtKB:  P03252
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03252
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
Pre-protein VI11Human adenovirus 2Mutation(s): 0 
UniProt
Find proteins for P03274 (Human adenovirus C serotype 2)
Explore P03274 
Go to UniProtKB:  P03274
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP03274
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
2UQ

Query on 2UQ



Download:Ideal Coordinates CCD File
D [auth A]N-benzyl-2-[(Z)-iminomethyl]pyrimidine-5-carboxamide
C13 H12 N4 O
LOHVEJATQLMRBB-MKMNVTDBSA-N
ACT

Query on ACT



Download:Ideal Coordinates CCD File
C [auth A]ACETATE ION
C2 H3 O2
QTBSBXVTEAMEQO-UHFFFAOYSA-M

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.59 Å
  • R-Value Free:  0.189 (Depositor), 0.187 (DCC) 
  • R-Value Work:  0.165 (Depositor), 0.163 (DCC) 
  • R-Value Observed: 0.166 (Depositor) 
Space Group: P 61
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 112.783α = 90
b = 112.783β = 90
c = 50.347γ = 120
Software Package:
Software NamePurpose
XSCALEdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2014-09-10
    Type: Initial release
  • Version 1.1: 2017-11-22
    Changes: Derived calculations, Other, Refinement description, Source and taxonomy
  • Version 1.2: 2023-09-27
    Changes: Data collection, Database references, Refinement description
  • Version 1.3: 2024-10-16
    Changes: Structure summary